IRX Therapeutics reports positive IRX-2 phase 2a head and neck squamous cell carcinoma clinical…
IRX Therapeutics presented results from a Phase 2a clinical trial of IRX-2, the company’s lead drug candidate, in head and neck squamous cell carcinoma (SCCHN) at the European Society…
Read More...
Read More...
